JP2007202835A - Iontophoresis apparatus - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To improve the efficiency of dosing drug ions in iontophoresis. <P>SOLUTION: The iontophoresis apparatus has an electrode, a drug holding part for holding drug ions and an ion selective membrane which lets the drug ions pass while shutting down the passage of biological counter ions and carries out the dosage of a living body with the drug ions through the ion selective membrane. It is further has a drug carrier medium part which is disposed on the front side of the ion selective membrane to get the drug ion of the first polarity or a medical fluid containing the drug ion of the first polarity carried and held on a medium. The ion selective member can be doped with the drug ions to hold. In this case, an ion holding part is disposed between the electrode and the ion selective membrane (drug holding part) to hold the electrolye. The drug holding part may be another membrane (drug holding part) different from the ion selective membrane to hold the drug containing the drug ions. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to an iontophoresis device for administering ionically dissociated drug ions to a living body driven by a voltage having the same polarity as the drug ions.

  An iontophoresis device generally includes a working electrode structure that holds drug ions dissociated into positive or negative ions, and a non-working electrode structure that serves as a counter electrode of the working electrode structure. Drug ions are administered into the living body by applying a voltage having the same polarity as the drug ions to the working electrode structure in a state where both the electrode structures are in contact with the living body skin.

  Patent Document 1 discloses an iontophoresis device in which an ion exchange membrane having the same polarity as a drug ion is disposed between a drug solution holding unit that holds a drug solution containing drug ions and the skin.

  In this iontophoresis device, the transfer of biological counter ions to the drug solution holding unit is blocked by the ion exchange membrane, so the amount of current consumed by the movement of biological counter ions is reduced, and the administration efficiency of drug ions is increased. It is possible to raise.

  However, in order to ensure smooth passage of drug ions, it is necessary to form pores of a size that allows the drug ions to pass through in the ion exchange membrane. Therefore, when a drug ion having a large molecular weight is administered, an ion exchange membrane having such a large pore is used, so that the blocking performance of biological counter ions is lowered and the administration efficiency of the drug ion is lowered. .

In addition, since counter ions with small molecular weight and high mobility such as Na ⁺ , H ⁺ , and Cl ⁻ are bonded to the ion exchange groups in the ion exchange membrane, these counter ions have priority over drug ions. Will shift to the living body side. For this reason, the iontophoresis device of Patent Document 1 has a problem that the rise of the dose is delayed particularly at the start of administration of drug ions.

Furthermore, since the skin surface has irregularities including skin appendages such as sweat lines and pores, it is difficult to completely adhere the entire surface of the ion exchange membrane to the skin. Therefore, biological counter ions from the skin easily flow out into the gap formed between the ion exchange membrane and the skin, and this also reduces the administration efficiency of drug ions.
US Pat. No. 5,395,310

  The present invention has been made in view of the above problems, and an object thereof is to provide an iontophoresis device capable of administering drug ions with higher efficiency.

The present invention
An electrode to which a first polarity voltage is applied;
An ion selective membrane disposed on the front side of the electrode and doped with drug ions of the first polarity, wherein the ion selective membrane allows passage of the drug ions while blocking passage of biological counter ions;
An ion source holding unit that is disposed between the electrode and the ion selective membrane and holds an electrolytic solution containing first polar ions supplied to the ion selective membrane;
An iontophoresis device comprising: a drug-carrying medium portion disposed on the front side of the ion-selective membrane and configured to carry and hold a first polar drug ion or a drug solution containing the first polar drug ion on a medium. A cis device (claim 1).

  In the present invention, the first polarity ions in the ion source holding unit (hereinafter, the first polarity ions in the ion source holding unit are referred to as “first electrolytic ions”) by the action of the first polarity voltage on the electrodes. Migrates to the ion selective membrane and replaces the drug ions doped in the ion selective membrane. The drug ion substituted by the first electrolytic ion is administered to the living body by the action of the first polarity voltage on the electrode.

  According to the present invention, drug ions are administered to a living body through an ion selective membrane that allows passage of drug ions and blocks passage of biological counter ions. The amount of current consumed by the movement can be reduced, and as a result, the drug ion administration efficiency can be increased.

  The ion-selective membrane in the present invention can take the form of a charge-selective membrane that allows passage of drug ions based on charges and blocks passage of biological counter ions, and allows passage of drug ions based on molecular weight. It can take the form of a semipermeable membrane that blocks the passage of biological counter ions.

According to the present invention, the following effects are achieved in addition to achieving the same effects as in Patent Document 1.
(1) Since drug ions are doped in an ion selective membrane, which is a member arranged close to the skin, further increase in drug ion administration efficiency can be expected.
(2) Doping drug ions in the ion selective membrane reduces the amount of counter ions such as Na ⁺ , H ⁺ , and Cl ⁻ in the ion selective membrane. It is possible to prevent a decrease in the drug ion administration efficiency due to the shift to, or to prevent a delay in the rise of the dose at the start of administration of the drug ion.
(3) Since the drug ions are held in a state of being doped in the ion selective membrane, the stability of the drug ions can be improved. For this purpose, the use amount of stabilizers, antibacterial agents, preservatives, etc. can be reduced. It can be reduced, or its use can be eliminated, or the storage period of the device can be extended.
(4) The concentration of biological counter ions such as Na ⁺ and Cl ⁻ existing on the skin can be lowered by the drug ions or the drug solution containing drug ions carried on the drug carrying medium part. Accordingly, the amount of biological counter ions passing through the ion selective membrane can be further reduced, and an ion selective membrane having pores of a somewhat large size is used to pass drug ions having a large molecular weight. Moreover, the fall of the administration efficiency of the drug ion by the movement of a biological counter ion can be suppressed.
(5) Since the drug-carrying medium part is configured to hold the drug ions or the drug solution containing the drug ions held in the medium, compared with the case where the drug solution is applied to the front side of the ion selective membrane. Thus, retention of drug ions or drug solutions can be improved.

  In order to effectively reduce the concentration of biological counter ions on the skin surface, a high concentration chemical solution is preferably used as the chemical solution held in the drug carrying medium portion of the present invention, and a saturated or supersaturated chemical solution is particularly preferable. used.

  The ion source holding part of the present invention can hold any electrolytic solution that can supply the first electrolytic ions to the ion selective membrane, but the mobility of the first electrolytic ions is smaller than that of the drug ions. Preferably, this can suppress a decrease in drug ion administration efficiency due to the first electrolytic ion competing with the drug ion.

  The ion source holding part of the present invention can also hold drug ions as the first electrolytic ions. When the same type of drug ion as that doped in the ion selective membrane is held as the first electrolytic ion, the problem that the first electrolytic ion becomes a competitive ion can be solved. In the case of holding a different type of drug ion from the drug ion doped in the ion selective membrane as an ion, the concentration of the drug ion in the ion source holding unit and / or the ion selective membrane according to the mobility of each drug ion By adjusting the dope amount of drug ions, an iontophoresis device capable of administering a plurality of types of drug ions at a desired ratio can be realized.

The present invention
An electrode to which a first polarity voltage is applied;
A chemical solution holding part disposed on the front side of the electrode and holding a chemical solution containing drug ions of the first polarity;
An ion-selective membrane that is disposed on the front side of the drug solution holding unit and that allows passage of drug ions while blocking passage of biological counter ions;
An iontophoresis device comprising: a drug-carrying medium portion disposed on the front side of the ion-selective membrane and configured to carry and hold a first polar drug ion or a drug solution containing the first polar drug ion on a medium. It can also be set as a cis apparatus (Claim 7).

  In the present invention, drug ions are administered to a living body through an ion selective membrane that allows the passage of drug ions and blocks the passage of biological counter ions. The amount of current consumed can be reduced, and as a result, the drug ion administration efficiency can be increased.

  The ion-selective membrane in the present invention can take the form of a charge-selective membrane that allows passage of drug ions based on charges and blocks passage of biological counter ions, and allows passage of drug ions based on molecular weight. It can take the form of a semipermeable membrane that blocks the passage of biological counter ions.

According to the present invention, the following effects are achieved in addition to the same effects as those of Patent Document 1.
(1) The concentration of biological counter ions such as Na ⁺ and Cl ⁻ existing on the skin can be reduced by the drug ions or the drug solution containing drug ions carried on the drug carrying medium part. Accordingly, the amount of biological counter ions passing through the ion selective membrane can be further reduced, and an ion selective membrane having pores of a somewhat large size is used to pass drug ions having a large molecular weight. Moreover, the fall of the administration efficiency of the drug ion by the movement of a biological counter ion can be suppressed.
(2) Since the drug-carrying medium part is configured to hold the drug ion or the drug solution containing the drug ion in a state of being held on the medium, compared with the case where the drug solution is applied to the front side of the ion selective membrane. Thus, retention of drug ions or drug solutions can be improved.

  As the medium of the drug-carrying medium part in the inventions of claims 1 and 7, it is preferable to use an ion exchange fiber, a polyelectrolyte gel or a surfactant, whereby the drug ion or the drug solution is retained in the drug-carrying medium part. The stability of drug ions can be improved.

  As the ion-exchange fiber, an ion-exchange fiber made of any ion-exchange polymer having a fibrous form, such as an ion-exchange fiber in which an ion-exchange group is introduced into a cross-linked insolubilized fibrous polystyrene, can be used.

  Ion exchange fiber can be used in the state of woven fabric or non-woven fabric, and its mechanical and chemical properties can be obtained by mixing other fibers such as polyamide fiber, polyester fiber, polyacrylic fiber and binder resin. It is also possible to use a modified product.

  When the drug ion held in the drug-carrying medium part is a cation, by using a cation exchange fiber as the ion exchange fiber, when the drug ion held in the drug-carrying medium part is an anion, By using an anion exchange fiber as the ion exchange fiber, a larger amount of drug ions can be more stably supported.

  A method of attaching a medium composed of ion exchange fibers to the front side of the ion selective membrane is arbitrary, and depending on the types of ion exchange fibers and ion selective membranes, both can be adhered or adhered satisfactorily by simply contacting the interface. There are cases where it can be done, and in cases where this is not the case, the two can be brought into close contact or bonded by an appropriate method according to the material such as hot press.

  Attachment of the ion exchange fiber to the ion selective membrane may be performed at the time of manufacture of the iontophoresis device, or may be performed immediately before use of the iontophoresis device (administration of drug ions).

  The process of supporting drug ions or a drug solution containing drug ions on the ion exchange fiber can be performed by impregnating the ion selective membrane with a predetermined concentration or a supersaturated drug solution in the ion exchange fiber. This process may be performed at any time before or after attachment of the ion exchange fiber to the ion selective membrane.

  The ion exchange fiber can increase the affinity for living skin by adjusting the amount of water as required. Therefore, by arranging ion exchange fibers on the front side of the ion selective membrane (interface with the skin), the adhesion of the working electrode structure to the skin is improved, and the drug ion administration efficiency is further increased. It becomes possible.

  As the polymer electrolyte gel, any solid polymer electrolyte gel containing a polar polymer as a main component can be used without particular limitation.

  Here, when the drug ion held in the drug-carrying medium portion is a cation, a polar polymer having many negatively charged polar groups such as a sulfonic acid group, a carboxyl group, a phosphoric acid group, and a phenol group is used. It can be preferably used, and this makes it possible to carry a larger amount of drug ions more stably. Specific examples of preferable polar polymers in this case include polystyrene sulfonic acid and polyacrylic acid.

  Similarly, when the drug ion held in the drug-carrying medium is an anion, the polarity has a number of positively charged polar groups such as a quaternary ammonium group, a quaternary pyridinium group, and a quaternary imidazole group. A polymer can be preferably used, and thereby, a larger amount of drug ions can be more stably supported. Specific examples of the preferred polar polymer in this case include a quaternary aminated styrene-divinylbenzene copolymer and a quaternary aminated styrene-butadiene copolymer.

  By allowing the polymer electrolyte gel to carry a chemical solution containing an ion dissociable drug, ion conductivity can be imparted to the polymer electrolyte gel. For the purpose of improving the conductivity and adjusting the properties of the polymer electrolyte gel, other ion dissociable salts and / or polar solvents can be blended.

  The method of attaching the medium made of the polymer electrolyte gel to the front surface side of the ion selective membrane is arbitrary, and depending on the type of the polymer electrolyte gel and the ion selective membrane, both can be adhered or adhered satisfactorily only by contacting the interface. If this is not the case, the two can be brought into close contact or bonded by an appropriate method according to the material such as hot press.

  The attachment of the polymer electrolyte gel to the ion selective membrane may be performed at the time of manufacture of the iontophoresis device, or may be performed immediately before use of the iontophoresis device (administration of drug ions).

  The process of supporting a drug ion or a drug solution containing a drug ion on the polymer electrolyte gel can be performed by impregnating the polymer electrolyte gel with a predetermined concentration or a supersaturated drug solution. This process may be performed at any time before or after attachment of the polymer electrolyte gel to the ion selective membrane.

  The polymer electrolyte gel can enhance the affinity for living skin by adjusting the amount of water as required. Therefore, by placing the polyelectrolyte gel on the front side of the ion selective membrane (interface with the skin), the adhesion of the working electrode structure to the skin is improved and the drug ion administration efficiency is further increased. It becomes possible to do.

  Any surfactant such as a nonionic surfactant, an anionic surfactant, and a cationic surfactant can be used as the surfactant without any particular limitation.

  Here, when the drug ion held in the drug-carrying medium part is a cation, by using an anionic surfactant, the drug ion held in the drug-carrying medium part is an anion. Can support a larger amount of drug ions more stably by using a cationic surfactant.

  Examples of the anionic surfactant in the present invention include sodium lauryl sulfate, sodium dodecylbenzenesulfonate, sodium alkylnaphthalenesulfonate, sodium dialkylsulfosuccinate, sodium alkyldiphenyl ether disulfonate, sodium polyoxyethylene laurylether sulfate, potassium oleate The cationic surfactant may be selected from laurylamine hydrochloride, laurylamine acetate, N-methyl, N-laurylamine hydrochloride, N, N-dimethyl, N-laurylamine 1,2,3 higher amine salt types such as hydrochloride, lauryltrimethylammonium chloride, cetyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldi It can be selected from such a chill benzyl ammonium chloride.

  When a surfactant is used as the medium, formation of the drug-carrying medium part on the front side of the ion selective membrane is necessary, for example, by applying a surfactant solution of an appropriate concentration to the front side surface of the ion selective membrane. After performing the drying treatment by the above, it can be carried out by applying the chemical solution in layers.

  When a surfactant is used as the medium of the drug-carrying medium part, it is possible to form a drug-carrying medium part that carries drug ions with a very thin film thickness. It is possible to achieve the effect of the present invention while minimizing the decrease in the drug ion administration efficiency due to the transition to the above.

  As the medium of the drug-carrying medium part in the first and seventh inventions, it is possible to use a porous film, an absorbent gel or a fiber sheet. In this case also, the retention of the drug solution in the drug-carrying medium part Can be increased.

  In addition, the porous membrane, the absorbent gel, or the fiber sheet can increase the affinity for living skin by appropriately selecting each material or adjusting the amount of water as necessary. Therefore, by arranging these media on the front side (interface with the skin) of the ion selective membrane, the adhesion of the working electrode structure to the skin is improved, and the drug ion administration efficiency is further increased. It is possible.

  As the porous film in the present invention, a porous film made of an arbitrary resin such as a polyolefin resin, a polyvinyl chloride resin, or a fluorine resin can be used. Preferably, the porosity or the absorption rate is high, A porous membrane that can be easily integrated with the ion selective membrane by pressing or the like can be used.

  As the absorbent gel in the present invention, any gel having excellent chemical solution absorbability can be used. By using hydrophilic gels such as polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylamide. It is also possible to increase the adhesion to the skin and further increase the drug ion administration efficiency.

  In the fiber sheet of the present invention, inorganic fibers such as silica fibers, alumina fibers, glass fibers, rock wool fibers, polyethylene fibers, nylon fibers, polyester fibers, aramid fibers, as long as a sufficient amount of chemical solution can be supported. It is possible to use organic fibers such as rayon, or woven fabrics and non-woven fabrics made of these mixed fibers without any particular limitation.

  Depending on the type of material used, the medium consisting of a porous membrane, absorbent gel, and fiber sheet may be able to adhere or adhere to each other simply by bringing the medium into contact with the ion selective membrane. Can be adhered or adhered to each other by an appropriate method according to the material such as hot press.

  The impregnation of the chemical solution into the medium composed of the porous membrane, the absorbent gel, and the fiber sheet may be performed before or after the medium is attached to the ion selective membrane. The attachment of these media to the ion selective membrane may be performed at the time of manufacturing the iontophoresis device or may be performed immediately before the use of the iontophoresis device (administration of drug ions).

  As the ion selective membrane in the present invention, it is possible to use a charge selective membrane that allows the passage of ions having the same polarity as the drug ions doped in the ion selective membrane while blocking the passage of ions of the opposite polarity. is there.

  As the ion selective membrane in the present invention, an ion exchange membrane can be particularly preferably used. When the drug ion doped in the ion selective membrane is a cation, a cation exchange membrane is used, and the ion selective membrane is used. An anion exchange membrane can be used when the drug ion doped into the membrane is an anion.

  The “drug” in the present specification has a certain medicinal effect or pharmacological action regardless of whether it is prepared or not, and treats, recovers or prevents a disease, promotes or maintains health, diagnoses a medical condition or health condition, etc. Or a substance administered to a living body for the purpose of promoting or maintaining beauty.

  The “drug ion” in the present specification means an ion that is generated by ion dissociation of a drug and is responsible for medicinal effect or pharmacological action.

  The “medical solution” in the present specification is not only a solution in which a drug is dissolved in a solvent or a liquid state such as a stock solution in the case where the drug is in a liquid state, as long as at least a part of the drug dissociates into drug ions In various states such as those suspended or emulsified in a solvent or the like, those prepared in the form of an ointment or paste, and the like.

  As used herein, “drug counter ion” means an ion present in a drug solution and having an opposite polarity to the drug ion.

  The drug ions held in the ion selective membrane, ion source holding part, drug carrying medium part or drug solution holding part of the present invention do not necessarily need to be a single type, and drug ions held in any one or more of them are There may be multiple types. In addition, the drug ions held in the ion selective membrane, ion source holding unit, drug carrying medium unit and drug solution holding unit of the present invention can all be the same type of drug ions, each of which is a different type of drug ion. It is also possible.

  “Skin” in the present specification means a surface of a living body on which drug ions can be administered by iontophoresis, and includes, for example, the oral mucosa. “Biological body” includes humans and animals.

  The “biological counter ion” in the present specification means an ion existing on or in the living body's skin and having a polarity opposite to that of the drug ion.

  In the present specification, the “front side” means the side close to the living skin on the current path upon administration of drug ions.

  In the present specification, the “first polarity” means a positive or negative electric polarity, and the “second polarity” means an electric polarity (negative or positive) opposite to the first polarity.

  As an ion exchange membrane, an ion exchange resin formed into a film shape, a heterogeneous ion exchange membrane obtained by dispersing an ion exchange resin in a binder polymer, and forming this by heat molding or the like, A composition comprising a monomer capable of introducing an exchange group, a crosslinkable monomer, a polymerization initiator, or a resin having a functional group capable of introducing an ion exchange group dissolved in a solvent is used as a cloth or a mesh. Alternatively, various ion exchange membranes such as a homogeneous ion exchange membrane obtained by impregnating and filling a substrate such as a porous film and performing an ion exchange group introduction treatment after polymerization or solvent removal are known. These various ion exchange membranes can be used without particular limitation for the ion exchange membrane of the present invention.

  In the present specification, the “first polarity ion exchange membrane” means an ion exchange membrane having a function of blocking the passage of ions of the second polarity while allowing passage of ions of the first polarity (that is, having the polarity of the first polarity). This means an ion exchange membrane in which ions pass more easily than ions of the second polarity. When the first polarity is positive, the “first polarity ion exchange membrane” is a cation exchange membrane, and when the first polarity is negative, the “first polarity ion exchange membrane” is an anion exchange membrane. is there.

  Similarly, the “second polarity ion exchange membrane” is an ion exchange membrane having a function of allowing passage of ions of the second polarity while blocking passage of ions of the second polarity (ie, ions of the second polarity). Means an ion exchange membrane that is easier to pass than ions of the first polarity. When the second polarity is positive, the “second polarity ion exchange membrane” is a cation exchange membrane, and when the second polarity is negative, the “second polarity ion exchange membrane” is an anion exchange membrane. is there.

  Specific examples of the cation exchange membrane include ion exchange membranes introduced with cation exchange groups such as Neocepta CM-1, CM-2, CMX, CMS, CMB manufactured by Tokuyama Corporation. Specific examples of the membrane include ion exchange membranes into which anion exchange groups such as Neocepta AM-1, AM-3, AMX, AHA, ACH, ACS, etc. manufactured by Tokuyama Corporation have been introduced.

  For the ion exchange membrane of the present invention, an ion exchange membrane of a type in which pores of a porous film are filled with an ion exchange resin can be particularly preferably used. Specifically, an average pore diameter of 0.005 to 5.0 μm, more preferably 0.01 to 2.0 μm, most preferably 0.02 to 0.2 μm (based on the bubble point method (JIS K3832-1990)). 5 to 140 μm, more preferably 10 to 95%, formed with a porosity of 20 to 95%, more preferably 30 to 90%, most preferably 30 to 60%. Using a porous film having a thickness of 120 μm, most preferably 15 to 55 μm, and an ion exchange resin with a filling rate of 5 to 95% by mass, more preferably 10 to 90% by mass, and particularly preferably 20 to 60% by mass. An ion exchange membrane filled with can be used.

  The “blocking of the passage of ions” described in this specification for an ion selective membrane, a charge selective membrane or an ion exchange membrane does not necessarily mean that no ions pass, but for example, the passage of ions at a certain speed. Even when the rate of passage or amount is sufficiently small compared to other specific ions, such as when the administration efficiency of drug ions can be sufficiently increased because the degree is small. It is.

  Similarly, “allowing the passage of ions” as described herein for an ion-selective membrane, a charge-selective membrane, or an ion-exchange membrane does not mean that there are no restrictions on the passage of ions, but the passage of ions. However, the rate of passage or the amount of passage is sufficiently large compared to other specific ions, such as when the administration efficiency of drug ions can be sufficiently increased because the degree is small. Includes cases.

  Hereinafter, embodiments of the present invention will be described with reference to the drawings.

  FIG. 1 is an explanatory diagram showing a configuration of an iontophoresis device 1 according to an embodiment of the present invention.

  As shown in the figure, the iontophoresis device 1 mainly includes a working electrode structure 10, a non-working electrode structure 20, and a power supply 30.

  The working electrode structure 10 includes an electrode 11 connected to one pole of a power supply 30 via a power supply line 31, an electrolyte solution holding unit 12 that holds an electrolyte solution that contacts the electrode 11, and the front surface of the electrolyte solution holding unit 12. The ion selective membrane 13 arranged on the side, the separator 14 arranged on the front side of the ion selective membrane 13, the ion source holding unit 15 arranged on the front side of the separator 14, and the front side of the ion source holding unit 15 are arranged. The ion-selective membrane 16 and the drug-carrying medium portion 17 disposed on the front side of the ion-selective membrane 16 are provided, and the whole is accommodated in a case or container 18.

  On the other hand, the non-working-side electrode structure 20 includes an electrode 21 connected to the other pole of the power supply 30 via a power supply line 32, an electrolyte solution holding unit 22 that holds an electrolyte solution that contacts the electrode 21, and an electrolyte solution holding unit. 22, an ion selective membrane 23 arranged on the front side of the ion selective membrane 23, an electrolyte holding unit 24 arranged on the front side of the ion selective membrane 23, and an ion selective membrane 25 arranged on the front side of the electrolytic solution holding unit 24. The whole is accommodated in a case or container 28.

  Although any conductive material can be used for the electrodes 11 and 21 without any particular limitation, an electrode using a conductive material having a lower oxidation-reduction potential than water, such as a silver / silver chloride electrode. It is possible to suppress the generation of gas and the generation of hydrogen ions, hydroxyl ions, hypochlorous acid, etc. by electrolysis of water.

Alternatively, a polarizable electrode containing a non-metallic conductor having a specific surface area of 10 m ² / g or more, such as activated carbon disclosed in Japanese Patent Application No. 2005-229984 by the applicant of the present application, or disclosed in Japanese Patent Application No. 2005-229985. It is also possible to suppress the generation of the above gas and ions due to electrolysis of water during energization by adopting an electrode containing a substance that causes an electrochemical reaction by doping or dedoping ions such as a conductive polymer. is there.

  In addition, when the amount of energization is small or the like, generation of gas or ions due to electrolysis of water is not a problem, or by appropriately selecting the electrolyte held in the electrolyte holding parts 12 and 22, In the case where generation of gas and ions due to decomposition can be prevented, an inert electrode such as gold, platinum, and stainless steel can be preferably used, and a carbon electrode that can reduce the concern about elution of metal ions and their transfer to a living body. Can be used particularly preferably. In this case, a composite carbon having a terminal member in which carbon is mixed in a polymer matrix disclosed in Japanese Patent Application No. 2004-317317 disclosed by the present applicant, and a conductive sheet made of carbon fiber or carbon fiber paper attached to the terminal member. Particularly, a composite carbon electrode having an electrode, a conductive sheet part and an extension part made of carbon fiber or carbon fiber paper disclosed in Japanese Patent Application No. 2005-222892, and a part of the extension part impregnated with a water repellent polymer It can be preferably used.

  The electrolytic solution holding parts 12 and 22 can hold an electrolytic solution in which an arbitrary electrolyte capable of ensuring the conductivity from the electrodes 11 and 21 to the ion selective membranes 13 and 23 can be retained. By using an electrolyte with a lower oxidation-reduction potential or using a buffer electrolyte solution in which multiple types of electrolytes are dissolved, gas generation and ion generation due to electrolysis of water during energization, or pH change due to this Can be suppressed.

  Examples of the electrolytic solution that can achieve the above object include a 5: 1 mixed solution of 0.5 M sodium fumarate and 0.5 M polyacrylic acid.

  The electrolytic solution holding unit 24 can hold an electrolytic solution in which an arbitrary electrolyte capable of ensuring the electrical conductivity from the ion selective membrane 23 to the ion selective membrane 25 is retained, and is an organic material that is particularly excellent in safety to the living body. Acids and physiological saline can be preferably retained.

  The ion source holding unit 15 ensures the conductivity from the ion selective membrane 13 to the ion selective membrane 16 and is the same as the drug ion for substituting the drug ion doped in the ion selective membrane 16 when energized. It is possible to hold an electrolytic solution in which an arbitrary electrolyte capable of supplying polar ions (first electrolytic ions) to the ion selective membrane 16 is dissolved.

  It is preferable that the electrolytic solution held in the ion source holding unit 15 does not include the first electrolytic ion having a mobility higher than that of the drug ion doped in the ion selective membrane 16, so that the first electrolytic ion is the drug ion. It is possible to prevent a decrease in drug ion administration efficiency due to competition with the drug.

  Or the electrolyte solution hold | maintained at the ion source holding | maintenance part 15 can also contain the drug ion D1 which should be administered to a biological body as a 1st electrolytic ion.

  In this case, the first electrolytic ion is the same type of drug ion as the drug ion D2 doped in the ion selective membrane 16, thereby reducing the administration efficiency of the drug ion D2 due to the competition between the first electrolytic ion and the drug ion D2. An iontophoresis device that administers a plurality of types of drug ions by making the first electrolytic ions different types of drug ions from the drug ions D2 doped in the ion selective membrane 16 1 can be realized.

  The electrolyte solution holding units 12, 22, 24 and the ion source holding unit 15 can hold each electrolyte solution in a liquid state, and impregnate an appropriate absorbent carrier such as gauze, filter paper, or aqueous gel. Can also be held.

  The ion selective membrane 13 preferably has a characteristic of blocking the passage of ions having the same polarity as the drug ions doped in the ion selective membrane 16 and allowing the passage of ions of the opposite polarity.

  By using such an ion selective membrane 13, energization is ensured by the transfer of ions having opposite polarities of drug ions from the ion source holding unit 15 to the electrolyte solution holding unit 12, while the electrolyte solution holding is performed from the ion source holding unit 15. It is possible to suppress the transfer of drug ions to the part 12 and the transfer of ions having the same polarity as the drug ions from the electrolyte solution holding part 12 to the ion source holding part 15. Therefore, decomposition or alteration of drug ions during energization can be prevented, or hydrogen ions or hydroxyl ions that may be generated by electrode reaction, or ions having high mobility contained in the electrolyte solution holding unit 12 are ion-selected. It is possible to prevent a decrease in drug ion administration efficiency or a change in pH value at the skin interface due to transfer to the membrane 16.

  In a particularly preferred embodiment, an ion exchange membrane having a polarity opposite to that of the drug ions D2 doped in the ion selective membrane 16 can be used as the ion selective membrane 13. That is, when the drug ion D2 is a cation, an anion exchange membrane is used as the ion selective membrane 13, and when the drug ion D2 is an anion, a cation exchange membrane is used as the ion selective membrane 13. Can do.

  It is preferable that the ion selective membrane 23 has a characteristic of allowing passage of ions having the same polarity as the drug ion D2 doped in the ion selective membrane 16 and blocking passage of ions having the opposite polarity.

  By using the ion selective membrane 23, it is possible to prevent the migration of hydrogen ions or hydroxyl ions, which may be caused by electrode reactions, to the electrolyte solution holding unit 24, and the resulting pH fluctuation at the living body interface.

  In a particularly preferred embodiment, an ion exchange membrane having the same polarity as the drug ions D2 doped in the ion selective membrane 16 can be used as the ion selective membrane 23. That is, a cation exchange membrane can be used as the ion selective membrane 23 when the drug ion D2 is a cation, and an anion exchange membrane can be used as the ion selective membrane 23 when the drug ion D2 is an anion. .

  The ion selective membrane 25 preferably has a characteristic of blocking the passage of ions having the same polarity as the drug ions D2 doped in the ion selective membrane 16 and allowing the passage of ions of the opposite polarity.

  By using the ion selective membrane 25 in combination with an electrolyte solution that is held in the electrolyte solution holding unit 24 and has excellent safety to the living body, it is possible to further increase the safety of administration of drug ions.

  In a particularly preferred embodiment, an ion exchange membrane having a polarity opposite to that of the drug ion D2 doped in the ion selective membrane 16 can be used as the ion selective membrane 25. That is, an anion exchange membrane can be used as the ion selective membrane 25 when the drug ion D2 is a cation, and a cation exchange membrane can be used as the ion selective membrane 25 when the drug ion D2 is an anion. .

  The ion selective membrane 16 preferably has a characteristic of allowing passage of ions having the same polarity as the drug ion D2 doped in the ion selective membrane 16 and blocking passage of ions of the opposite polarity.

  By using such an ion selective membrane 16, it is possible to effectively suppress the migration of biological counter ions to the ion source holding unit 15 and achieve an increase in drug ion administration efficiency.

  In a particularly preferred embodiment, as the ion selective membrane 16, an ion exchange membrane having the same polarity as the drug ion D2 doped into the ion selective membrane 16 can be used. That is, a cation exchange membrane can be used as the ion selective membrane 16 when the drug ion D2 is a cation, and an anion exchange membrane can be used as the ion selective membrane 16 when the drug ion D2 is an anion. .

  The ion selective membrane 16 is doped with drug ions D2 to be administered to the living body.

  FIG. 1 schematically shows an aspect of retaining drug ions D2 when an ion exchange membrane of a type in which an ion exchange resin is filled in the pores P of the porous film F is used as the ion selective membrane 16. ing. As shown in the drawing, it is considered that at least a part of the drug ion D2 is held in a state of being bonded to an ion exchange group G1 introduced into an ion exchange resin (not shown) in the pore P.

  The ion selective membrane 16 can be doped with the drug ions D2 by immersing the ion selective membrane 16 in a chemical solution containing drug ions D2 having an appropriate concentration for a predetermined time. The dope amount of the drug ion D2 to the ion selective membrane 16 can be adjusted by the concentration of the chemical solution to be used, the immersion time, the number of immersions, and the like.

  Between the ion selective membrane 13 and the ion source holding part 15, a separator 14 which is preferably a sheet-like member made of a water-impermeable material can be disposed. The separator 14 is disposed so as to cover the entire cross section inside the container 18 in order to block the movement of ions and molecules between the ion selective membrane 13 and the ion source holding unit 15. In the illustrated example, in order to facilitate the removal of the separator 14, the end e of the separator is led out of the container 18, and the separator 14 is removed by pulling the end e. be able to. It is also possible to apply a release agent to one or both sides of the separator 14, so that the separator 14 can be easily removed.

  On the front side of the ion selective membrane 16, a drug-carrying medium portion constituted by a medium M made of an ion-exchange fiber or a polymer electrolyte gel carrying a drug ion D 3 having the same polarity as the drug ion D 2 or a drug solution containing the drug ion D 3. 17 is arranged.

  Here, if the drug ion D3 is a cation, a cation exchange fiber can be preferably used as the ion exchange fiber, and the polymer electrolyte gel is based on a polar polymer having many negatively charged polar groups. The polymer electrolyte gel can be preferably used. If the drug ion D3 is an anion, an anion exchange fiber can be preferably used as the ion exchange fiber, and the polymer electrolyte gel is a high polymer based on a polar polymer having many positively charged polar groups. A molecular electrolyte gel can be preferably used.

  When ion exchange fibers are used as the medium M, as shown schematically in the figure, all or part of the drug ions D3 in the drug carrying medium portion 17 are bonded to the ion exchange groups G2 in the ion exchange fibers. Similarly, when a polymer electrolyte gel is used as the medium M, all or part of the drug ions D3 in the drug-carrying medium part 17 are bonded to the polar group G2 of the polar polymer. Retained.

  Depending on the conditions for introducing the drug ion D3 into the drug-carrying medium part 17, etc., it is also possible to retain a part of the drug ion D3 in an ionic state in the chemical liquid impregnated in the medium M. Alternatively, the medium M may be impregnated with a supersaturated chemical solution so that a part of the drug ion D3 is retained as a salt bonded to the drug counter ion.

  The introduction of the drug ion D3 into the medium M can be performed, for example, by impregnating the medium M with an appropriate concentration or supersaturated chemical solution containing the drug ion D3. The drug-carrying medium portion 17 can be formed by introducing the drug ions D3 into the medium M after the medium M is disposed on the front surface side of the ion selective membrane 16 and adhered thereto, or can be formed on the medium M. After introducing the drug ions D3, the medium M can be formed by adhering or adhering to the front surface side of the ion selective membrane 16.

  The drug ions D3 carried on the drug carrying medium part 17 can be the same type of drug ions as the drug ions D1 or D2, or can be different types of drug ions.

  The containers 18 and 28 of the working side electrode structure 10 and the non-working side electrode structure 20 are formed of an arbitrary material such as plastic in which spaces for accommodating the above-described elements are formed and the lower surface is opened. It is a member. The containers 18 and 28 are preferably made of a material that can prevent evaporation of moisture from the inside and entry of foreign matter from the outside, and a flexible material that can follow the movement of the living body and the unevenness of the skin. In addition, the lower surfaces 18b and 28b of the containers 18 and 28 are made of an appropriate material capable of preventing evaporation of moisture and mixing of foreign matters during storage of the iontophoresis device 1, and are removed from use (not shown). Furthermore, it is also possible to provide a pressure-sensitive adhesive layer for improving adhesion to living skin on the outer peripheral edges of the lower surfaces 18b and 28b of the containers 18 and 28, and the like.

The power source 30, battery, voltage regulator, a constant current device, may be used, such as constant current, constant voltage device, 0.01~1.0mA / cm ^2, preferably, from 0.01 to 0. It is preferable to use a constant current device that can adjust the current in the range of 5 mA / cm ² and operates under a safe voltage condition of 50 V or less, preferably 30 V or less.

  In the iontophoresis device 1, the separator 14 and the liner (not shown) are removed, and the drug carrying medium portion 17 of the working electrode structure 10 and the ion selective membrane 25 of the non-working electrode structure 20 are brought into contact with the living skin. In this state, by applying a voltage having the same polarity as that of the drug ion D2 and a voltage having the opposite polarity to the electrodes 11 and 21, respectively, the drug ions D2 and D3 are administered to the living body. When the drug ion D1 having a certain degree of mobility is held as the first electrolytic ion of the ion source holding unit 15, the drug ion D1 is administered to the living body together with the drug ions D2 and D3.

In the iontophoresis device 1, the concentration of biological counter ions such as Na ⁺ and Cl ⁻ existing on the skin can be reduced by the drug-carrying medium part 17 that carries the drug ions D3 or the drug solution containing the drug ions D3. Therefore, the amount of biological counter ions passing through the ion selective membrane 16 is reduced, and the drug ion administration efficiency is improved. Further, since at least a part of the drug ion D3 is supported in a state of being bonded to the ion exchange group of the ion exchange fiber or the polar group of the polymer electrolyte gel, the retention of the drug ion D3 is improved, and the device is stored during storage. The stability of the drug ion D3 is improved. Furthermore, since the medium M made of ion exchange fibers or polymer electrolyte gel can increase the affinity for living body skin by adjusting the amount of water in the medium M as necessary, the working electrode It is possible to improve the adhesion of the structure 10 to the living skin and further increase the drug ion administration efficiency.

  In addition, the electrolyte solution holding parts 12, 22, 24, the ion selective membranes 13, 23, 25, the separator 14, the liner (not shown), and the like in the above embodiment are optional components. It is also possible to delete some or all of the components.

  In the illustrated example, the separator 14 is disposed between the ion selective membrane 13 and the ion source holding unit 15, but the separator 14 may be disposed between the electrolytic solution holding unit 12 and the ion selective membrane 13. is there.

  FIGS. 2A to 2C are explanatory views showing, in an enlarged manner, the form of the separator 14 that can be used particularly preferably in the above embodiment and the use form thereof.

  The separator 14 in FIG. 2 has one end e1 attached to one side wall of the container 18, an intermediate portion m folded back on the other side wall of the container 18, and the other end e2 led out from the one side wall of the container 18. .

  In the iontophoresis device 1 having the separator 14, the separator 14 can be removed in the manner shown in FIGS. 2B and 2C by pulling the other end e2 in the direction of the arrow. The ease of removal can be increased.

  In addition, also in the separator 14 shown in FIG. 2, the removal operation | movement of the separator 14 can be further facilitated by apply | coating a mold release agent to the upper surface u and / or the lower surface b.

  FIG. 3A is an explanatory diagram showing a configuration of a working electrode structure 10a of another embodiment that can be used in place of the working electrode structure 10 in the iontophoresis device 1, and FIG. The same or similar elements are given the same or similar reference numerals.

  The working electrode structure 10a is a drug composed of a medium M composed of a surfactant S carrying a drug ion D3 having the same polarity as the drug ion D2 or a drug solution containing the drug ion D3 on the front side of the ion selective membrane 16. The structure is the same as that of the working electrode structure 10 except that the carrier medium portion 17a is disposed.

  As the surfactant S, any of nonionic surfactants, anionic surfactants and cationic surfactants can be suitably used regardless of whether the drug ion D3 is positive or negative. is there.

  However, if the drug ion D3 is a cation, an anionic surfactant is used as the surfactant S, and if the drug ion D3 is an anion, a cationic surfactant is used as the surfactant S. As a result, the retention of the drug ion D3 in the drug carrying medium part 17a can be improved.

  The surfactant S has a tendency to adsorb lipophilic groups on the surface of the ion selective membrane 16 and to orient the hydrophilic groups in the opposite direction (downward in FIG. 3A). All or a part is held in a state of being bonded to the hydrophilic group of the surfactant S as schematically shown in the figure.

  In addition to the drug ion D3 in a state of being bonded to the surfactant S as described above, the drug solution and / or drug ion D3 in which the drug ion D3 is dissolved is bonded to the drug counter ion on the drug carrying medium portion 17a. It is also possible to retain the drug precipitated as a salt.

  In the iontophoresis device 1 including the working electrode structure 10a, drug ions are administered in the same manner as described above for the iontophoresis device 1 including the working electrode structure 10 shown in FIG.

In the iontophoresis device 1 including the working electrode structure 10a, biological counter ions such as Na ⁺ and Cl ⁻ that are present on the skin by the drug-carrying medium portion 17a that carries the drug ions D3 or the drug solution containing the drug ions D3. Therefore, the amount of biological counter ions passing through the ion selective membrane 16 is reduced, and the administration efficiency of drug ions is improved. Further, since the drug ion D3 is held in a state of being bound to the surfactant S, the retention of the drug ion D3 is improved, and the stability of the drug ion D3 during storage of the apparatus is improved. Furthermore, in the working electrode structure 10a, the drug-carrying medium part 17a can be formed with a very thin film thickness, so that administration of drug ions by transfer of biological counter ions from the living body into the drug-carrying medium part 17a is possible. It is possible to minimize the decrease in efficiency.

  FIG. 3B is an explanatory diagram showing a configuration of a working electrode structure 10b of still another aspect that can be used in place of the working electrode structure 10 in the iontophoresis device 1. FIG. The same or similar elements are denoted by the same or similar reference numerals.

  The working electrode structure 10b is constituted by a medium M made of a porous membrane, an absorbent gel or a fiber sheet impregnated with a drug solution containing drug ions D3 having the same polarity as the drug ions D2 on the front side of the ion selective membrane 16. It has the same configuration as that of the working electrode structure 10 except that the drug-carrying medium portion 17b is arranged.

  In the iontophoresis device 1 including the working electrode structure 10b, drug ions are administered in the same manner as described above for the iontophoresis device 1 including the working electrode structure 10 shown in FIG.

In the iontophoresis device 1 including the working electrode structure 10b, the concentration of biological counter ions such as Na ⁺ and Cl ⁻ existing on the skin is reduced by the drug carrying medium portion 17b carrying the drug solution containing the drug ion D3. Therefore, the amount of biological counter ions that pass through the ion selective membrane 16 is reduced, and the administration efficiency of drug ions is improved. In addition, the medium M made of a porous membrane, an absorbent gel or a fiber sheet can increase the affinity for living body skin by adjusting the amount of water in the medium M as necessary. It is possible to improve the adhesion of the electrode structure 10b to the living skin and further increase the drug ion administration efficiency.

  In addition, the electrolyte solution holding part 12, the ion selective membrane 13, the separator 14 and the liner (not shown) in the working side electrode structures 10a and 10b are optional components as in the working side electrode structure 10. All or a part of these can be omitted.

  FIG. 4 is an explanatory view showing a configuration of a working electrode structure 10c of still another aspect that can be used in place of the working electrode structure 10 in the iontophoresis device 1, and is the same as FIG. Similar elements are labeled with the same or similar symbols.

  As shown in the drawing, the working electrode structure 10c includes an electrode 11 connected to one pole of a power supply 30 via a power supply line 31, an electrolyte holding unit 12 that holds an electrolyte in contact with the electrode 11, an electrolysis An ion selective membrane 13 disposed on the front side of the liquid holding unit 12, a separator 14 disposed on the front side of the ion selective membrane 13, a chemical solution retained on the front side of the separator 14 and holding a chemical solution containing drug ions D <b> 2. Part 15c, an ion selective membrane 16c arranged on the front side of the chemical solution holding part 15c, and a drug-carrying medium part 17c arranged on the front side of the ion selective film 16c, all of which are accommodated in a container 18. .

  The electrode 11, the electrolyte solution holding unit 12, the ion selective membrane 13, the separator 14, and the container 18 in the working electrode structure 10 c can have the same configuration as that of the working electrode structure 10.

  The drug solution holding part 15c holds a drug solution containing drug ions D2 having an appropriate concentration. The chemical liquid holding unit 15c can hold the chemical liquid in a liquid state, and can also be held by impregnating an appropriate absorbent carrier such as gauze, filter paper, or aqueous gel.

  The ion selective membrane 16c preferably has a characteristic that allows passage of ions having the same polarity as the drug ions D2 in the drug solution holding unit 15c and blocks passage of ions of the opposite polarity.

  By using such an ion selective membrane 16c, it is possible to effectively inhibit the migration of biological counter ions to the drug solution holding unit 15c, and to achieve an increase in drug ion administration efficiency.

  In a particularly preferred embodiment, as the ion selective membrane 16c, an ion exchange membrane having the same polarity as the drug ion D2 in the drug solution holding unit 15c can be used. That is, when the drug ion D2 is a cation, a cation exchange membrane can be used as the ion selective membrane 16c, and when the drug ion D2 is an anion, an anion exchange membrane can be used as the ion selective membrane 16c. .

  The drug-carrying medium part 17c can have the same configuration as the drug-carrying medium part 17, 17a, or 17b in the working electrode structure 10, 10a, or 10b.

  In the iontophoresis device 1 having the working electrode structure 10c, the drug carrying medium portion 17c of the working electrode structure 10c and the ion selective membrane 25 of the non-working electrode structure 20 are in contact with the living skin. Thus, by applying a voltage having the same polarity as that of the drug ion D2 and a voltage having the opposite polarity to the electrodes 11 and 21, respectively, the drug ions D2 and D3 are administered to the living body.

In the iontophoresis device 1 having the working electrode structure 10c, biological counter ions such as Na ⁺ and Cl ⁻ that are present on the skin by the drug-carrying medium portion 17c that carries the drug ions D3 or the drug solution containing the drug ions D3. Therefore, the amount of biological counter ions passing through the ion selective membrane 16 is reduced, and the administration efficiency of drug ions is improved.

  In particular, when an ion exchange fiber or a polymer electrolyte gel is used as the medium M of the drug carrying medium portion 17c, at least a part of the drug ion D3 is an ion exchange group of the ion exchange fiber or a polar group of the polymer electrolyte gel. Therefore, the retention of the drug ion D3 is improved, and the stability of the drug ion D3 during storage of the device is improved. Since the medium M made of ion exchange fibers or polymer electrolyte gel can increase the affinity for living skin by adjusting the amount of water in the medium M as necessary, the working electrode structure It is possible to improve the adhesion of 10c to living skin and further increase the administration efficiency of drug ions.

  Even when a surfactant is used as the medium M of the drug-carrying medium part 17c, since at least a part of the drug ion D3 is supported while bound to the surfactant, the retention of the drug ion D3 is improved, The stability of the drug ion D3 during storage of the device is improved. In this case, since the drug-carrying medium part 17c can be formed in a very thin film thickness, the drug ion administration efficiency is reduced due to the transfer of biological counter ions from the living body into the drug-carrying medium part 17c. It can be minimized.

  Also in the working electrode structure 10c, the electrolyte solution holding unit 12, the ion selective membrane 13, the separator 14 and the like are optional components, and some or all of these components from the iontophoresis device 1 are used. It is also possible to delete.

  In the illustrated example, the separator 14 is disposed between the ion selective membrane 13 and the chemical solution holding unit 15c. However, the separator 14 may be disposed between the electrolytic solution holding unit 12 and the ion selective membrane 13. .

  As mentioned above, although this invention was demonstrated based on some embodiment, this invention is not limited to these embodiment, A various change is possible within description of a claim.

  For example, in the above-described embodiment, an iontophoresis device including a working electrode structure that holds a drug to be administered to a living body and a non-working electrode structure that serves as a counter electrode has been described as an example. An iontophoresis device in which a drug to be administered to a living body is held in both of two electrode structures connected to both poles of a power supply, and an iontophoresis in which a plurality of electrode structures are connected to each pole of a power supply The present invention can be similarly applied to the lysis apparatus.

  In the case of an iontophoresis device having a plurality of working electrode structures, it is not necessary that all working electrode structures have a drug-carrying medium part, but at least one action having a drug-carrying medium part. Iontophoresis devices having side electrode structures are within the scope of the present invention.

  Alternatively, the iontophoresis device itself is not provided with the non-working side electrode structure, but, for example, one or a plurality of working side electrode structures are brought into contact with the living skin, and a part of the living body is placed on a member serving as a ground It is also possible to administer a drug by applying a voltage to the working electrode structure in a state in which the drug is in contact.

  In the above embodiment, the case where the working electrode structure, the non-working electrode structure, and the power source are configured as separate bodies has been described. However, these elements are incorporated into a single casing, or these are assembled. It is also possible to improve the handleability by forming the entire apparatus incorporated into a sheet or patch.

BRIEF DESCRIPTION OF THE DRAWINGS Explanatory drawing which shows the structure of the iontophoresis apparatus which concerns on one Embodiment of this invention. BRIEF DESCRIPTION OF THE DRAWINGS Explanatory drawing which shows the form of the separator which can be preferably used in the iontophoresis apparatus which concerns on this invention, and its usage aspect. (A), (B) is explanatory drawing which shows the structure of the working side electrode structure of the other aspect used for the iontophoresis apparatus which concerns on this invention. Explanatory drawing which shows the structure of the working side electrode structure of the other aspect used for the iontophoresis apparatus which concerns on this invention.

Explanation of symbols

DESCRIPTION OF SYMBOLS 1 ... Iontophoresis apparatus 10, 10a-10c ... Working side electrode structure 20 ... Non-working side electrode structure 11, 21 ... Electrode 12, 22, 24 ... Electrolyte holding Units 13, 16, 16c, 23, 25 ... ion selective membrane 14 ... separator 15 ... ion source holding unit 15c ... drug solution holding unit 17, 17a-17c ... drug carrying medium unit 18, 28 ... Container 30 ... Power source 31, 32 ... Feed lines D1-D3 ... Drug ions G1, G2 ... Ion exchange group

Claims (11)

An electrode to which a first polarity voltage is applied;
An ion selective membrane disposed on the front side of the electrode and doped with drug ions of the first polarity, wherein the ion selective membrane allows passage of the drug ions while blocking passage of biological counter ions;
An ion source holding unit that is disposed between the electrode and the ion selective membrane and holds an electrolytic solution containing first polar ions supplied to the ion selective membrane;
An iontophoresis device comprising: a drug-carrying medium portion disposed on the front side of the ion-selective membrane and configured to carry and hold a first polar drug ion or a drug solution containing the first polar drug ion on a medium. Cis equipment.   The iontophoresis device according to claim 1, wherein the medium of the drug-carrying medium part is an ion exchange fiber, a polymer electrolyte gel, or a surfactant.   The iontophoresis device according to claim 1, wherein the medium of the drug-carrying medium part is a porous film, an absorbent gel, or a fiber sheet.   The iontophoresis device according to any one of claims 1 to 3, wherein drug ions having a first polarity are held in the ion source holding unit.   5. The charge selection membrane according to claim 1, wherein the ion selective membrane is a charge selective membrane that allows passage of ions of the first polarity while blocking passage of ions of the second polarity. 6. Iontophoresis equipment.   The iontophoresis device according to any one of claims 1 to 5, wherein the ion selective membrane is a first polarity ion exchange membrane. An electrode to which a first polarity voltage is applied;
A chemical solution holding part disposed on the front side of the electrode and holding a chemical solution containing drug ions of the first polarity;
An ion-selective membrane that is disposed on the front side of the drug solution holding unit and that allows passage of drug ions while blocking passage of biological counter ions;
An iontophoresis device comprising: a drug-carrying medium portion disposed on the front side of the ion-selective membrane and configured to carry and hold a first polar drug ion or a drug solution containing the first polar drug ion on a medium. Cis equipment.   The iontophoresis device according to claim 7, wherein the medium of the drug-carrying medium part is an ion exchange fiber, a polymer electrolyte gel, or a surfactant.   8. The iontophoresis device according to claim 7, wherein the medium of the drug-carrying medium part is a porous film, an absorbent gel, or a fiber sheet.   The iontophoresis device according to any one of claims 7 to 9, wherein the ion selective membrane is a charge selective membrane that selectively allows ions of the first polarity to pass therethrough. The iontophoresis device according to any one of claims 7 to 10, wherein the ion selective membrane is a first polarity ion exchange membrane.

Images